Table 1.
Demographic and clinical characteristics of the study population.
| Overall | Negative biopsy | PCa | ||
|---|---|---|---|---|
| Parameter | (n = 315) | (n = 121) | (n = 194) | P value |
| Age (median [IQR]), years | 69.00 [64.00, 73.00] | 68.00 [61.00, 73.00] | 69.00 [65.00, 73.00] | 0.118 |
| MRI PI-RADS (%) | <0.001 | |||
| 1 | 10 (3.2) | 8 (6.6) | 2 (1.0) | |
| 2 | 94 (29.8) | 57 (47.1) | 37 (19.1) | |
| 3 | 97 (30.8) | 36 (29.8) | 61 (31.4) | |
| 4 | 77 (24.4) | 17 (14.0) | 60 (30.9) | |
| 5 | 37 (11.7) | 3 (2.5) | 34 (17.5) | |
| Prostate volume (median [IQR]), mL | 36.04 [26.63, 56.58] | 50.40 [32.55, 73.63] | 32.94 [24.36, 43.08] | <0.001 |
| tPSA (median [IQR]), ng/mL | 9.97 [6.09, 16.54] | 8.66 [5.03, 14.26] | 10.71 [7.04, 18.97] | 0.001 |
| fPSA (median [IQR]), ng/mL | 1.42 [0.85, 2.31] | 1.43 [0.89, 2.13] | 1.39 [0.84, 2.43] | 0.915 |
| p2PSA (median [IQR]), pg/mL | 36.06 [21.31, 57.14] | 24.76 [13.04, 40.80] | 42.68 [26.66, 67.74] | <0.001 |
| %fPSA (median [IQR]) | 13.36 [9.62, 19.22] | 15.90 [10.75, 22.72] | 12.04 [9.04, 16.73] | <0.001 |
| %p2PSA (median [IQR]) | 25.02 [16.54, 35.80] | 17.33 [12.31, 26.14] | 28.23 [20.98, 39.05] | <0.001 |
| PHI (median [IQR]) | 78.40 [52.33, 118.11] | 53.22 [35.86, 76.63] | 96.99 [70.12, 150.43] | <0.001 |
| PSAD (median [IQR]), ng/mL/mL | 0.24 [0.15, 0.51] | 0.17 [0.10, 0.28] | 0.29 [0.19, 0.66] | <0.001 |
| PHID (median [IQR]) | 2.09 [1.03, 3.63] | 1.01 [0.70, 1.79] | 2.91 [1.85, 4.80] | <0.001 |
PI-RADS, Prostate Imaging Reporting and Data System; tPSA, total prostate specific antigen; p2PSA, [−2]proPSA; %fPSA,free PSA/total PSA;%p2PSA, p2PSA/free PSA; PHI, prostate health index; PSAD, PSA density, PSA/Prostate volume; PHID, PHI density, PHI/Prostate volume.